In a previous study we found that serum starvation of DLBCL cells, followed by re-addition of serum without or with mTOR inhibitors, revealed consistent changes in protein expression.32 Taking this approach, we observed modest and variably reduced expression (~2-fold) of MCL-1, BCL-xL and survivin among MLN0128 and SBI-756 treated cells (Fig. S8a, b). The gene discussed is BCL2L1; the disease is diffuse large B-cell lymphoma.